Clinical trials (such as SUSTAIN-6) have shown cardiovascular benefits in people with type 2 diabetes taking semaglutide, though it does not have a specific UK indication for cardiovascular risk reduction
Emerging Players The emerging players in the glucagon-like peptide 1 (GLP-1) analogues market include Gmax Biopharm., Sciwind Biosciences Co., Ltd., Teva Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC (Hikma), Viking Therapeutics, Terns Pharmaceuticals, Inc., Altimmune, AVVA Pharmaceuticals Ltd, LEXICARE PHARMA PVT
The first step in the pre-operative care of a patient on GLP-1RAs should involve an assessment of the risk of aspiration, taking into account factors that may increase this risk, including the escalation phase of GLP-1RA dosing or a high-dose protocol, the presence of gastrointestinal symptoms of delayed gastric emptying (e.g
Retatrutide, a much-hyped injection that is in the works, can apparently lead to nearly 30 percent loss in body weight on average
Aetna isn't selling marketplace health insurance plans in Florida for 2026